MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

Cumberland Pharmaceuticals Inc

Fermé

3.18 -0.93

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.98

Max

3.2

Chiffres clés

By Trading Economics

Revenu

-2M

-735K

Ventes

-876K

11M

Marge bénéficiaire

-6.784

Employés

91

EBITDA

-878K

414K

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+12.18% upside

Dividendes

By Dow Jones

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-13M

47M

Ouverture précédente

4.11

Clôture précédente

3.18

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Cumberland Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 oct. 2025, 23:30 UTC

Actions en Tendance

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 oct. 2025, 21:21 UTC

Résultats

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 oct. 2025, 00:00 UTC

Acquisitions, Fusions, Rachats

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 oct. 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 oct. 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 oct. 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 oct. 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 oct. 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 oct. 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 oct. 2025, 22:54 UTC

Market Talk
Acquisitions, Fusions, Rachats

Scales's JV Buyout Lauded by Bull -- Market Talk

2 oct. 2025, 22:54 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Forex and Fixed Income Roundup: Market Talk

2 oct. 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 oct. 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 oct. 2025, 21:17 UTC

Acquisitions, Fusions, Rachats

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 oct. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Energy & Utilities Roundup: Market Talk

2 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 oct. 2025, 20:49 UTC

Acquisitions, Fusions, Rachats

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 oct. 2025, 20:00 UTC

Acquisitions, Fusions, Rachats

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 oct. 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 oct. 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 oct. 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 oct. 2025, 18:45 UTC

Acquisitions, Fusions, Rachats

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 oct. 2025, 18:45 UTC

Acquisitions, Fusions, Rachats

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 oct. 2025, 18:44 UTC

Acquisitions, Fusions, Rachats

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 oct. 2025, 18:44 UTC

Acquisitions, Fusions, Rachats

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 oct. 2025, 18:44 UTC

Acquisitions, Fusions, Rachats

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 oct. 2025, 18:43 UTC

Acquisitions, Fusions, Rachats

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparaison

Variation de prix

Cumberland Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

12.18% hausse

Prévisions sur 12 Mois

Moyen 3.5 USD  12.18%

Haut 3.5 USD

Bas 3.5 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

1 ratings

0

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

4.325 / 4.845Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
help-icon Live chat